Cost-effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma - PubMed
5 hours ago
- #cost-effectiveness
- #multiple myeloma
- #bispecific antibody
- The study conducts a cost-effectiveness analysis comparing teclistamab plus daratumumab versus ciltacabtagene autoleucel for relapsed multiple myeloma.
- Teclistamab combined with daratumumab is evaluated as a bispecific antibody therapy, while ciltacabtagene autoleucel represents a CAR-T-cell therapy option.
- Key clinical trials referenced include NEJM studies on teclistamab plus daratumumab (2025), teclistamab alone (2022), and ciltacabtagene autoleucel versus standard care (2023).
- Additional references discuss risk evaluation and mitigation strategies for CAR-T-cell therapy access and infection risks with bispecific antibodies in B-cell malignancies.